A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively

The advent of checkpoint inhibitor therapy in medical oncology has led to an increase in hospitalizations for immune-related adverse effects. Severe colitis has been reported in approximately 5% of patients treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, such as ipilimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Delasos, Lukas, Desai, Aakash, Lopetegui Lia, Nerea, Kethireddy, Nikhila, Ray, Carolyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679838/
https://www.ncbi.nlm.nih.gov/pubmed/31428491
http://dx.doi.org/10.1155/2019/9069354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679838/
https://www.ncbi.nlm.nih.gov/pubmed/31428491
http://dx.doi.org/10.1155/2019/9069354

Ejemplares similares